Peter Green's questions to Kura Oncology Inc (KURA) leadership • Q2 2025
Question
Peter Green, on for Charles Zhou, asked for details on patient baselines for the upcoming KO-2806 data in RCC at ESMO and inquired about plans for additional data disclosures for Zifdomenib in the relapsed/refractory NPM1 setting.
Answer
Chief Medical Officer Dr. Mollie Leoni stated that while she could not preempt the ESMO abstract, the RCC data would include a typical, varied Phase 1 patient population. She also confirmed that a publication for the Zifdomenib monotherapy data should be expected in the coming months.